SAFE-T seeks collaboration with similar initiatives to establish strong links and networks in the field of biomarkers research and thus improve further the quality of research results. At the moment the collaboration agreements are in the process of negotiation or signed with:
Critical Path Institute’s PSTC consortium to increase the clinical and biological evidence by sharing data and knowledge and to share experience of a public-public partnership with the common objective of improving the process of drug development. To utilize synergies in terms of preclinical and clinical qualification work.
Spanish DILI Registry to contribute with additional cases of patient population having liver injury and provide expertise in DILI epidemiology.
Spanish DILI Registry has an important experience in the field, being already active for more than 10 years. The Registry has 713 DILI cases induced by various pharmaceuticals registered and 56 hospitals in Spain contribute to the Registry.
Málaga University (UMA) provides expertise in DILI epidemiology and facilitates the collaboration with Spanish DILI Registry
Centre for Drug Safety Science at Liverpool University to contribute with additional cases of patient population having liver injury and provide expertise in terms of mechanistic DILI biomarkers.